{"id":"asc40","safety":{"commonSideEffects":[{"rate":null,"effect":"Elevated transaminases"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL3661754","moleculeType":"Small molecule","molecularWeight":"439.56"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ASC40 targets the HBV core antigen and inhibits capsid assembly, preventing the formation of infectious viral particles. By blocking this critical step in the HBV replication cycle, the drug reduces viral load and may promote immune clearance of infected hepatocytes. This mechanism represents a novel approach distinct from nucleos(t)ide reverse transcriptase inhibitors and integrase inhibitors.","oneSentence":"ASC40 is a hepatitis B virus (HBV) capsid assembly modulator that disrupts viral particle formation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:02:35.849Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B infection"}]},"trialDetails":[{"nctId":"NCT03179904","phase":"PHASE2","title":"TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2017-08-03","conditions":"Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8","enrollment":17},{"nctId":"NCT06248008","phase":"PHASE3","title":"A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne Vulgaris","status":"COMPLETED","sponsor":"Ascletis Pharmaceuticals Co., Ltd.","startDate":"2024-04-18","conditions":"Acne","enrollment":240},{"nctId":"NCT06192264","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of ASC40 (Denifanstat) Tablets in the Treatment of Patients With Moderate to Severe Acne Vulgaris","status":"COMPLETED","sponsor":"Ascletis Pharmaceuticals Co., Ltd.","startDate":"2024-01-23","conditions":"Acne","enrollment":480},{"nctId":"NCT05104125","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne Vulgaris","status":"COMPLETED","sponsor":"Ascletis Pharmaceuticals Co., Ltd.","startDate":"2022-01-12","conditions":"Acne Vulgaris","enrollment":180},{"nctId":"NCT05118776","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ascletis Pharmaceuticals Co., Ltd.","startDate":"2022-01-21","conditions":"Recurrent Glioblastoma","enrollment":136},{"nctId":"NCT04843449","phase":"PHASE1","title":"Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics of ASC40 in Healthy Subjects","status":"COMPLETED","sponsor":"Ascletis Pharmaceuticals Co., Ltd.","startDate":"2021-04-04","conditions":"Healthy","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ASC40","genericName":"ASC40","companyName":"Ascletis Pharmaceuticals Co., Ltd.","companyId":"ascletis-pharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ASC40 is a hepatitis B virus (HBV) capsid assembly modulator that disrupts viral particle formation. Used for Chronic hepatitis B infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}